The outlook for patients with stage IV melanoma has remained relatively unchanged over the last 40 years, until this last year when ipilimumab and vemurafenib were introduced for patients with unresectable and metastatic melanoma. But are these wonder drugs all they promise to be? The answer is complex.
More News